Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2).

Carcinogenesis - 1 Sept 1999

Lunn R M, Bell D A, Mohler J L, Taylor J A

Abstract excerpt

Prostate cancer is the most common malignancy in males and is the second most common cause of cancer mortality in American men. Polymorphisms have been identified in two genes, the 17-hydroxylase cytochrome P450 gene (CYP17) and the steroid 5-reductase type II gene (SRD5A2) that are involved with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 3-Oxo-5-alpha-Steroid 4-Dehydrogenase
Share to Black People
Share to Dihydrotestosterone

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasms, Hormone-Dependent

Share to North Carolina

Share to Steroid 17-alpha-Hydroxylase

Share to Taiwan

Share to Testosterone

Source

Identifiers

PMID: 10469617
DOI: 10.1093/carcin/20.9.1727

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-10469617-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2).PMID 10469617Read ↗

The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer.Semantic proximity Read ↗

The association of 5alpha-reductase II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population.Semantic proximity Read ↗

Genetic polymorphism in sex hormone metabolism and prostate cancer risk.Semantic proximity Read ↗

A polymorphism in the CYP17 gene and risk of prostate cancer.Semantic proximity Read ↗

Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways.Semantic proximity Read ↗

Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development.Semantic proximity Read ↗

Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.Semantic proximity Read ↗

Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer risk.Semantic proximity Read ↗

Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.Semantic proximity Read ↗

Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR.Semantic proximity Read ↗

Polymorphism in the Androgen Biosynthesis Gene (CYP17), a Risk for Prostate Cancer: A Meta-Analysis.Semantic proximity Read ↗

CYP17, SRD5A2, CYP1B1, and CYP2D6 gene polymorphisms with prostate cancer risk in North Indian population.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.